DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 636--------------------------------------------------
       First-line Tysabri in MS: rationale, patient selection, benefits
        and risks
       By: agate Date: January 29, 2015, 12:47 pm
       ---------------------------------------------------------
       "First-line natalizumab in multiple sclerosis: rationale,
       patient selection, benefits and risks" is an article by
       researchers at the Ohio State University MS Center  appearing in
       Therapeutic Advances in Therapeutic Disease (March 2014). The
       entire article can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926344/.
       *****************************************************